Experiment Protocol Biomedical Engineer in United States Miami –Free Word Template Download with AI

This Experiment Protocol outlines the methodology for evaluating a novel wearable biosensor designed for continuous glucose monitoring (CGM). The research is conducted by a team of Biomedical Engineers at the Miami Biomedical Research Institute, located in United States Miami. The high prevalence of diabetes in the region, coupled with the diverse demographic profile of Miami, makes it an ideal location for this study. The biosensor aims to provide real-time glucose readings with improved accuracy and comfort compared to existing devices.

The primary objective is to assess the device's performance in a real-world setting, focusing on accuracy, user comfort, and data reliability. Secondary objectives include evaluating the device's impact on patient quality of life and its potential to reduce healthcare costs.

This is a prospective, single-arm, observational study. Participants will use the wearable biosensor for a period of 30 days. Data will be collected continuously and compared against standard blood glucose measurements. The study will be conducted in compliance with all relevant regulations in the United States, including those enforced by the Food and Drug Administration (FDA) and the Institutional Review Board (IRB) of the Miami Biomedical Research Institute.

Inclusion Criteria:

• Age 18-65 years
• Diagnosed with Type 1 or Type 2 diabetes
• Currently using a standard glucose monitoring device
• Resident of Miami-Dade County, United States Miami
• Ability to provide informed consent

Exclusion Criteria:

• Pregnancy or breastfeeding
• Severe skin conditions at the sensor application site
• History of adverse reactions to adhesives
• Participation in another clinical trial within the past 30 days

4.1. Recruitment and Consent:

Participants will be recruited through local healthcare facilities in Miami. Informed consent will be obtained in both English and Spanish to accommodate the diverse population of United States Miami.

4.2. Device Application:

A Biomedical Engineer will apply the wearable biosensor to the participant's upper arm. The application site will be cleaned and prepared according to standard protocols. Participants will be instructed on how to use the device and the accompanying mobile application.

4.3. Data Collection:

Participants will wear the biosensor for 30 days. They will also perform standard blood glucose tests twice daily using their existing device. Data from both the biosensor and the standard device will be recorded and uploaded to a secure server.

4.4. Follow-Up:

Participants will have weekly check-ins with the research team to address any issues and ensure compliance. At the end of the study, participants will complete a survey assessing their experience with the device.

Data will be analyzed using statistical software. The primary endpoint is the mean absolute relative difference (MARD) between the biosensor readings and the standard blood glucose measurements. Secondary endpoints include user satisfaction scores and the frequency of device-related adverse events.

This study has been approved by the IRB of the Miami Biomedical Research Institute. All participants will provide written informed consent. Data will be anonymized and stored securely in compliance with HIPAA regulations. Participants can withdraw from the study at any time without penalty.

Potential risks include skin irritation at the sensor application site and minor discomfort. Participants will be provided with a contact number for the research team in case of any adverse events. The Biomedical Engineer overseeing the study will monitor all reported issues and take appropriate action.

This Experiment Protocol provides a comprehensive framework for evaluating the novel wearable biosensor in a real-world setting. The study leverages the expertise of Biomedical Engineers and the unique demographic characteristics of United States Miami to ensure robust and generalizable results. The findings will contribute to the advancement of diabetes management technologies and improve patient care.